{"id":"https://openalex.org/W4362525379","doi":"https://doi.org/10.1158/2326-6066.c.6550500","title":"Data from Demographic Factors Associated with Toxicity in Patients Treated with Anti\u2013Programmed Cell Death-1 Therapy","display_name":"Data from Demographic Factors Associated with Toxicity in Patients Treated with Anti\u2013Programmed Cell Death-1 Therapy","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362525379","doi":"https://doi.org/10.1158/2326-6066.c.6550500"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6550500","doi":"https://doi.org/10.1158/2326-6066.c.6550500","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6550500","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/2326-6066.c.6550500","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079665603","display_name":"Kaustav P. Shah","orcid":"https://orcid.org/0000-0001-6866-0003","observed_orcids":["https://orcid.org/0000-0001-6866-0003"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaustav P. Shah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054901630","display_name":"Haocan Song","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Haocan Song","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100357202","display_name":"Fei Ye","orcid":"https://orcid.org/0000-0001-6472-5076","observed_orcids":["https://orcid.org/0000-0001-6472-5076"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fei Ye","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019401898","display_name":"Javid J. Moslehi","orcid":"https://orcid.org/0000-0001-5443-4312","observed_orcids":["https://orcid.org/0000-0001-5443-4312"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Javid J. Moslehi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089113899","display_name":"Justin Micah Balko","orcid":"https://orcid.org/0000-0002-4263-5974","observed_orcids":["https://orcid.org/0000-0002-4263-5974"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Justin M. Balko","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4263-5974","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086895898","display_name":"Joe\u2010Elie Salem","orcid":"https://orcid.org/0000-0002-0331-3307","observed_orcids":["https://orcid.org/0000-0002-0331-3307"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joe-Elie Salem","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas B. Johnson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9789999723434448},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9860000014305115},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8629999756813049},{"id":"https://openalex.org/keywords/age-as-risk-factor","display_name":"age as risk factor","score":0.9240000247955322},{"id":"https://openalex.org/keywords/colitis","display_name":"colitis","score":0.7390000224113464},{"id":"https://openalex.org/keywords/hepatitis","display_name":"hepatitis","score":0.9710000157356262},{"id":"https://openalex.org/keywords/myocarditis","display_name":"myocarditis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/pneumonitis","display_name":"pneumonitis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9229999780654907},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.6290000081062317},{"id":"https://openalex.org/keywords/length-of-hospital-stay","display_name":"length of hospital stay","score":0.7760000228881836},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.7549999952316284},{"id":"https://openalex.org/keywords/vigibase","display_name":"VigiBase","score":0.7279999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8336673974990845},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8146834373474121},{"id":"https://openalex.org/C2779524853","wikidata":"https://www.wikidata.org/wiki/Q1284347","display_name":"Pneumonitis","level":3,"score":0.7267755270004272},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.6575779318809509},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.6347405910491943},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5852687358856201},{"id":"https://openalex.org/C2780875844","wikidata":"https://www.wikidata.org/wiki/Q186235","display_name":"Myocarditis","level":2,"score":0.5721317529678345},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5620729923248291},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4290595054626465},{"id":"https://openalex.org/C144301174","wikidata":"https://www.wikidata.org/wiki/Q7893852","display_name":"Univariate analysis","level":3,"score":0.41506534814834595},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4020328223705292},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.3752949833869934},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.23693513870239258},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.21935677528381348},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6066.c.6550500","doi":"https://doi.org/10.1158/2326-6066.c.6550500","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6550500","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6550500","doi":"https://doi.org/10.1158/2326-6066.c.6550500","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6550500","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3021418236","https://openalex.org/W3083504612","https://openalex.org/W3169161113","https://openalex.org/W4414287004","https://openalex.org/W4387807276","https://openalex.org/W3160711784","https://openalex.org/W3030611024","https://openalex.org/W4393084820","https://openalex.org/W2890894484","https://openalex.org/W2979129241"],"abstract_inverted_index":{"Abstract":[0],"Immune":[1],"checkpoint":[2,152],"inhibitors":[3],"(ICI)":[4],"are":[5,44],"now":[6],"routinely":[7],"used":[8],"in":[9,126,139,143,172],"multiple":[10],"cancers":[11],"but":[12,84],"may":[13],"induce":[14],"autoimmune-like":[15],"side":[16],"effects":[17],"known":[18],"as":[19],"immune-related":[20],"adverse":[21],"events":[22],"(irAE).":[23],"Although":[24],"classical":[25],"autoimmune":[26],"diseases":[27],"have":[28],"well-known":[29],"risk":[30],"factors,":[31],"including":[32],"age,":[33],"gender,":[34],"and":[35,64,89,103,121,131,142,156],"seasonality,":[36],"the":[37],"clinical":[38],"factors":[39],"that":[40,72],"lead":[41],"to":[42,115],"irAEs":[43,83,88,171],"not":[45,160],"well-defined.":[46],"To":[47],"explore":[48],"these":[49],"questions,":[50],"we":[51],"assessed":[52],"455":[53],"patients":[54,99],"with":[55,59,77,150,154,182],"advanced":[56],"melanoma":[57],"treated":[58],"ICI":[60],"at":[61],"our":[62,140],"center":[63,141],"a":[65,78,116,162],"large":[66],"pharmacovigilance":[67],"database":[68],"(VigiBase).":[69],"We":[70,158],"found":[71],"younger":[73,127],"age":[74,136],"was":[75,112,147],"associated":[76,181],"similar":[79],"rate":[80],"of":[81,106,170,191],"any":[82],"more":[85,90,101,124],"frequent":[86],"severe":[87],"hospitalizations":[91,179],"(OR,":[92],"0.97":[93],"per":[94],"year).":[95],"Paradoxically,":[96],"however,":[97],"older":[98,135],"had":[100,133],"deaths":[102],"increased":[104,184],"length":[105],"stay":[107],"(LOS)":[108],"when":[109],"hospitalized.":[110],"This":[111,145,186],"partially":[113],"due":[114],"distinct":[117],"toxicity":[118],"profile:":[119],"Colitis":[120],"hepatitis":[122],"were":[123,180],"common":[125],"patients,":[128],"whereas":[129],"myocarditis":[130],"pneumonitis":[132],"an":[134],"distribution":[137],"both":[138],"VigiBase.":[144],"pattern":[146],"particularly":[148],"apparent":[149],"combination":[151],"blockade":[153],"ipilimumab":[155],"nivolumab.":[157],"did":[159],"find":[161],"link":[163],"between":[164],"gender":[165],"or":[166,174],"seasonality":[167],"on":[168],"development":[169],"univariate":[173],"multivariate":[175],"analyses,":[176],"although":[177],"winter":[178],"marginally":[183],"LOS.":[185],"study":[187],"identifies":[188],"age-specific":[189],"associations":[190],"irAEs.":[192]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-06T00:00:00"}